Daniel Liebler
Faculty Member
Last active: 2/15/2016

  1. Integrative omics analysis reveals the importance and scope of translational repression in microRNA-mediated regulation. Liu Q, Halvey PJ, Shyr Y, Slebos RJ, Liebler DC, Zhang B (2013) Mol Cell Proteomics 12(7): 1900-11
    › Primary publication · 23550052 (PubMed) · PMC3708174 (PubMed Central)
  2. Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS). Abbatiello SE, Mani DR, Schilling B, Maclean B, Zimmerman LJ, Feng X, Cusack MP, Sedransk N, Hall SC, Addona T, Allen S, Dodder NG, Ghosh M, Held JM, Hedrick V, Inerowicz HD, Jackson A, Keshishian H, Kim JW, Lyssand JS, Riley CP, Rudnick P, Sadowski P, Shaddox K, Smith D, Tomazela D, Wahlander A, Waldemarson S, Whitwell CA, You J, Zhang S, Kinsinger CR, Mesri M, Rodriguez H, Borchers CH, Buck C, Fisher SJ, Gibson BW, Liebler D, Maccoss M, Neubert TA, Paulovich A, Regnier F, Skates SJ, Tempst P, Wang M, Carr SA (2013) Mol Cell Proteomics 12(9): 2623-39
    › Primary publication · 23689285 (PubMed) · PMC3769335 (PubMed Central)
  3. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Ellis MJ, Gillette M, Carr SA, Paulovich AG, Smith RD, Rodland KK, Townsend RR, Kinsinger C, Mesri M, Rodriguez H, Liebler DC, Clinical Proteomic Tumor Analysis Consortium (CPTAC) (2013) Cancer Discov 3(10): 1108-12
    › Primary publication · 24124232 (PubMed) · PMC3800055 (PubMed Central)
  4. Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. Lin D, Alborn WE, Slebos RJ, Liebler DC (2013) J Proteome Res 12(12): 5996-6003
    › Primary publication · 24224610 (PubMed) · PMC3864264 (PubMed Central)
  5. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V (2013) BMC Syst Biol : S1
    › Primary publication · 24564859 (PubMed) · PMC4029366 (PubMed Central)
  6. Basophile: accurate fragment charge state prediction improves peptide identification rates. Wang D, Dasari S, Chambers MC, Holman JD, Chen K, Liebler DC, Orton DJ, Purvine SO, Monroe ME, Chung CY, Rose KL, Tabb DL (2013) Genomics Proteomics Bioinformatics 11(2): 86-95
    › Primary publication · 23499924 (PubMed) · PMC3737598 (PubMed Central)
  7. Amended safety assessment of formaldehyde and methylene glycol as used in cosmetics. Boyer IJ, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2013) Int J Toxicol 32(6 Suppl): 5S-32S
    › Primary publication · 24335968 (PubMed)
  8. The development of selected reaction monitoring methods for targeted proteomics via empirical refinement. Bereman MS, MacLean B, Tomazela DM, Liebler DC, MacCoss MJ (2012) Proteomics 12(8): 1134-41
    › Primary publication · 22577014 (PubMed) · PMC3643124 (PubMed Central)
  9. Safety assessment of trimoniums as used in cosmetics. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2012) Int J Toxicol 31(6 Suppl): 296S-341S
    › Primary publication · 23283705 (PubMed)
  10. Safety assessment of stearyl heptanoate and related stearyl alkanoates as used in cosmetics. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2012) Int J Toxicol 31(5 Suppl): 141S-6S
    › Primary publication · 23064772 (PubMed)